Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT00482495
Phase
PHASE2
Status
Completed

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • gene expression analysis — GENETIC
  • protein expression analysis — GENETIC
  • laboratory biomarker analysis — OTHER

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of multiple myeloma by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory multiple myeloma.

Key Dates

First listed
Jun 5, 2007
Start date
Apr 30, 2006
Status verified
May 2011
Primary completion
Dec 31, 2006
Completion
Nov 30, 2009

Study Design

Enrollment
42 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Confirmed hematologic response

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55940-

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies